https://www.nasdaq.com/press-release/axsome-therapeutics-reports-third-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/axsome-therapeutics-to-report-third-quarter-2021-financial-results-on-november-8-2021
https://www.nasdaq.com/press-release/axsome-therapeutics-expands-term-loan-facility-with-hercules-capital-to-%24300-million
https://www.nasdaq.com/press-release/axsome-therapeutics-initiates-symphony-phase-3-trial-of-axs-12-in-narcolepsy-2021-09
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-fda-acceptance-of-new-drug-application-for-axs-07-for
https://www.nasdaq.com/press-release/axsome-therapeutics-provides-update-on-the-new-drug-application-for-axs-05-for-the
https://www.nasdaq.com/press-release/axsome-therapeutics-reports-second-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-axs-05-achieves-primary-and-key-secondary-endpoints-in
https://www.nasdaq.com/press-release/axsome-therapeutics-to-report-second-quarter-2021-financial-results-on-august-9-2021
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-planned-nda-submission-for-axs-14-for-the-management-of
https://www.nasdaq.com/press-release/axsome-therapeutics-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/axsome-therapeutics-joins-mental-health-america-and-other-advocacy-organizations-in
https://www.nasdaq.com/press-release/axsome-therapeutics-to-report-first-quarter-2021-financial-results-on-may-10-2021
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug
https://www.nasdaq.com/press-release/axsome-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/axsome-therapeutics-to-present-at-upcoming-investor-conferences-2021-02-19
https://www.nasdaq.com/press-release/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on
https://www.nasdaq.com/press-release/axsome-therapeutics-initiates-accord-phase-3-trial-of-axs-05-in-alzheimers-disease
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-positive-efficacy-and-safety-results-from-the-phase-3
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-positive-results-from-the-comet-si-trial-of-axs-05-in
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-positive-results-from-the-comet-trd-trial-of-axs-05-in
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-positive-efficacy-and-safety-results-from-phase-3-comet
https://www.nasdaq.com/press-release/axsome-therapeutics-reports-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/axsome-therapeutics-and-veeva-systems-partner-to-build-axsomes-digital-centric
https://www.nasdaq.com/press-release/axsome-therapeutics-and-veeva-systems-partner-to-build-axsomes-digital-centric-0
https://www.nasdaq.com/press-release/axsome-therapeutics-to-present-data-from-the-advance-1-trial-of-axs-05-in-alzheimers
https://www.nasdaq.com/press-release/axsome-therapeutics-to-report-third-quarter-2020-financial-results-on-november-5-2020
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-%24225-million-term-loan-facility-with-hercules-capital
https://www.nasdaq.com/press-release/axsome-therapeutics-presents-new-data-from-momentum-phase-3-trial-with-axs-07
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-expedited-development-of-axs-12-for-the-treatment-of
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-axs-07-phase-3-migraine-trial-results-selected-by-the
https://www.nasdaq.com/press-release/axsome-therapeutics-presents-new-data-from-gemini-phase-3-trial-with-axs-05
https://www.nasdaq.com/press-release/axsome-therapeutics-to-present-new-data-for-axs-05-in-major-depressive-disorder-at
https://www.nasdaq.com/press-release/axsome-therapeutics-to-present-at-the-morgan-stanley-18th-annual-global-healthcare
https://www.nasdaq.com/press-release/axsome-therapeutics-to-present-at-upcoming-investor-conferences-2020-09-03
https://www.nasdaq.com/press-release/axsome-therapeutics-confirms-pivotal-status-and-advancement-of-axs-05-for-the
https://www.nasdaq.com/press-release/axsome-therapeutics-to-present-data-from-the-concert-phase-2-trial-of-axs-12-in
https://www.nasdaq.com/press-release/axsome-therapeutics-completes-successful-fda-pre-nda-meeting-for-axs-07-for-the-acute
https://www.nasdaq.com/press-release/axsome-therapeutics-reports-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-further-progress-in-axs-05-depression-clinical-program
https://www.nasdaq.com/press-release/axsome-therapeutics-receives-fda-breakthrough-therapy-designation-for-axs-12-for-the
https://www.nasdaq.com/press-release/axsome-therapeutics-to-report-second-quarter-2020-financial-results-on-august-10-2020
https://www.nasdaq.com/press-release/axsome-therapeutics-completes-successful-fda-pre-nda-meeting-for-axs-05-for-the
https://www.nasdaq.com/press-release/axsome-therapeutics-receives-fda-breakthrough-therapy-designation-for-axs-05-for-the
https://www.nasdaq.com/press-release/axsome-therapeutics-to-present-at-upcoming-investor-conferences-2020-06-04
https://www.nasdaq.com/press-release/axsome-therapeutics-presents-data-from-gemini-phase-3-trial-of-axs-05-in-major
https://www.nasdaq.com/press-release/axsome-therapeutics-to-host-2020-annual-meeting-of-stockholders-virtually-2020-05-26
https://www.nasdaq.com/press-release/axsome-therapeutics-reports-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/axsome-therapeutics-to-report-first-quarter-2020-financial-results-on-may-8-2020-2020
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-in-the-advance-1
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-axs-07-achieves-both-co-primary-endpoints-and-prevents
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-topline-results-of-the-stride-1-phase-3-trial-in
https://www.nasdaq.com/press-release/axsome-therapeutics-accelerates-completion-of-the-advance-1-phase-2-3-trial-of-axs-05
https://www.nasdaq.com/press-release/axsome-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-the-promotion-of-mark-jacobson-to-chief-operating
https://www.nasdaq.com/press-release/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results-on
https://www.nasdaq.com/press-release/axsome-therapeutics-completes-patient-enrollment-in-the-intercept-phase-3-trial-of
https://www.nasdaq.com/press-release/axsome-therapeutics-to-present-at-upcoming-investor-conferences-2020-02-19
https://www.nasdaq.com/press-release/axsome-therapeutics-completes-patient-randomization-in-the-stride-1-phase-3-trial-of
https://www.nasdaq.com/press-release/thinking-about-buying-stock-in-apple-axsome-therapeutics-crocs-lululemon-athletica-or
https://www.nasdaq.com/press-release/axsome-therapeutics-enters-into-exclusive-license-agreement-with-pfizer-inc.-for
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-axs-07-achieves-co-primary-and-key-secondary-endpoints
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-closing-of-%24200-million-public-offering-of-common-stock
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-pricing-of-public-offering-of-%24174-million-of-shares-of
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-proposed-public-offering-of-common-stock-2019-12-18
https://www.nasdaq.com/press-release/axsome-therapeutics-added-to-nasdaq-biotechnology-index-2019-12-17
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-in-gemini-phase-3
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-in-concert-phase-2
https://www.nasdaq.com/press-release/axsome-therapeutics-to-host-investor-rd-call-with-key-opinion-leaders-focusing-on-axs
https://www.nasdaq.com/press-release/axsome-therapeutics-reports-third-quarter-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/axsome-therapeutics-to-report-third-quarter-2019-financial-results-on-november-7-2019
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-results-of-mindset-physician-survey-affirming-unmet
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-continued-progress-in-clinical-development-of-axs-07
https://www.nasdaq.com/press-release/axsome-therapeutics-completes-patient-enrollment-in-the-concert-phase-2-trial-of-axs
https://www.nasdaq.com/press-release/axsome-therapeutics-announces-completion-of-patient-enrollment-in-the-gemini-phase-3
https://www.nasdaq.com/press-release/axsome-therapeutics-to-provide-update-on-continued-progress-at-the-2019-cantor-global
